서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 12 of 12

Issue DateTitle / Author(s) / CitationFileAltmetrics
2011-01
A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinonna harboring EGFR mutations
DOI
2014-09
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
DOI
2014-11
A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma
view fileDOI
2016-04
Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial
view fileDOI
2018-02
Phase I pharmacokinetic study of nivolumab in Korean patients with advanced solid tumors
DOI
2018-08
Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy
DOI
2019-01
Landscape of actionable genetic alterations profiled from 1,071 tumor samples in Korean cancer patients
DOI
2019-09
Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial
DOI
2020-03
Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis
DOI
2022-01
Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
DOI
2023-09
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With <i>EGFR</i>-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301
DOI
2024-01
Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset
DOI
1